Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • RFK Jr.’s Future
  • Melanoma Drug
  • Charity Care Gap
  • Search for New FDA Chief

WHAT'S NEW

  • RFK Jr.'s Future
  • Melanoma Drug
  • Charity Care Gap
  • Search for New FDA Chief

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Oct 27 2021

Full Issue

MRNA Vaccines To Be Made In Africa In BioNTech Deal With Senegal, Rwanda

BioNTech and Pfizer are responsible for one of the leading covid vaccines, based on mRNA technology, and this deal will see vaccines using the tech made in Africa. Meanwhile, Moderna has pledged up to 110 million doses of its vaccine to help the continent vaccinate people against covid.

AP: BioNTech To Work With Senegal, Rwanda To Make MRNA Vaccines

Senegal and Rwanda have signed an agreement with German company BioNTech for the construction of its first start-to-finish factories to make messenger RNA vaccines in Africa. BioNTech, which developed the Pfizer-BioNTech COVID-19 vaccine, said Tuesday that construction will start in mid-2022. It is working with the Institut Pasteur in Dakar, Senegal’s capital, and the Rwandan government, a statement said. (Petesch, 10/26)

AP: Moderna To Supply Africa With Up To 110 Million COVID Doses

Moderna on Tuesday said it will make up to 110 million doses of its COVID-19 vaccine available to African countries, which local officials called a breakthrough on the world’s least vaccinated continent. The announcement said Moderna is prepared to deliver the first 15 million doses by the end of this year, with 35 million in the first quarter of 2022 and up to 60 million in the second quarter. It says “all doses are offered at Moderna’s lowest tiered price.” (Anna, 10/26)

In other global covid news —

Bloomberg: Serious Covid Cases In The U.K. Hit Levels Last Seen In March

The U.K. reported its highest daily death toll from coronavirus since the beginning of March, adding to fears that tighter restrictions might be needed this winter. The number of people hospitalized is also at the highest since that period. Steadily increasing hospitalization and death rates have put pressure on the government to enact its “Plan B,” which could include mandatory face coverings and a recommendation to work from home. (Capel, 10/26)

AP: Beijing Confirms Strict 'Closed Loop' For Winter Olympics

Chinese organizers have confirmed participants in next year’s Winter Olympics will be strictly isolated from the general population and could face expulsion for violating COVID-19 restrictions. Vice mayor and Beijing 2022 organizing committee official Zhang Jiandong told reporters Wednesday that those taking part in the games beginning Feb. 4 must remain in a “closed loop” for training, competing, transport, dining and accommodation. (10/27)

In other developments —

CIDRAP: H3N2 Strain Makes Early Mark On Europe's Flu Season

Though flu cases are still low in Europe, an unusually early spike in Croatia is a sign that the 2021-22 flu season could be severe for older people, the European Centre for Disease Prevention and Control (ECDC) said today. The ECDC said the main subtype detected in the region over the past month is influenza A H3N2, which is known for disproportionately affecting older people and has been linked to lower vaccine effectiveness. It said the early signals suggest the season could be severe for older people but noted the timing of flu circulation may vary among countries. (10/26)

Bloomberg: WHO Clears HPV Shot From China’s Innovax To Ease Global Shortage

The World Health Organization approved a cervical cancer vaccine from China’s Beijing Wantai Biological Pharmacy Enterprise Co., broadening access in developing countries to a scarce shot that prevents one of the most common causes of cancer. The inoculation was developed by Wantai’s vaccine subsidiary Xiamen Innovax Biotech Co. and works against the two highest-risk types of human papillomavirus, a sexually-transmitted virus that can cause cervical cancer. It received a stamp of approval from the WHO, known as a prequalification, which is widely recognized by developing nations as proof of a product’s safety and efficacy. (10/26)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 15
  • Thursday, May 14
  • Wednesday, May 13
  • Tuesday, May 12
  • Monday, May 11
  • Friday, May 8
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF